Bicycle Therapeutics plc (BCYC)
Healthcare
- Fundamental
- 3
- Sentiment
- 2
- Technical
- 1
Do Nothing: qualitativeScore is 2 (below required floor of 3), and avgDollarVolume20 is only $1.27M versus the $5M minimum.
Company overview
Bicycle Therapeutics plc is a clinical-stage biopharmaceutical company based in Cambridge, UK, focused on developing innovative therapies for diseases lacking effective treatments. Its lead investigational product, BT1718, is a Bicycle Toxin Conjugate targeting specific tumor expressions, currently in Phase I/IIa trials. The company also explores treatments beyond oncology, including a plasma kallikrein inhibitor for diabetic macular edema.
Fundamental
fairStrong liquidity contrasts with weak profitability and high cash burn.
Clinical-stage biotech with a very strong cash position (SEC 10-Q shows $510.1M cash at 2026-06-30 and at least 12 months of runway) and low debt, but still burning cash heavily (TTM free-cash-flow yield about -76%) with deeply negative profitability (TTM net margin about -311%). Collaboration revenue has been volatile and fell sharply after partnership terminations, so performance remains highly dependent on clinical and partnering execution. Shares trade at a large discount to cash and analyst targets imply upside, but the setup is high-uncertainty and catalyst-driven.
Sentiment
weakSentiment has drifted negative with no clear catalysts in sight.
Recent media sentiment is slightly negative (last ~14d polarity_score ≈ -0.13 at aggregator tier) and modestly worse than the 30–90d baseline (≈ -0.04), with coverage focused on pipeline prioritization uncertainty and a small bearish rating note; the official GlobeNewswire PR scan surfaced no new company-issued catalysts. Reddit chatter is effectively absent and the legal screen found no cases, though the investigation analyzer failed to extract text (no confirmed regulator action surfaced in discovery).
Technical
very weakThe stock remains in a strong downtrend with insufficient volume for a reversal.
Chart quality is poor: BCYC is below SMA20/50/200, below EMA9/21 and daily VWAP, with RSI below 50 and MACD still below zero; ADX at 51.59 confirms the dominant trend is down rather than a bullish base.
You’re looking at 2026-08-17 — more than 2 trading days ago.
Subscribers saw this then, and see today’s score, verdict and trade plan now.
More Healthcare
Not financial advice. For informational and educational purposes only.